SavedAdd your journal

Journals / Turkish journal of nephrology (Online) / 2020 / Cilt: 29 - Sayı: 3

Molecular Targeted Cancer Therapies and the Kidney

Özge BAŞ AKSU
Rezzan Eren SADİOĞLU
Şule ŞENGÜL
Pages
232–241
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Novel, targeted anticancer therapies have increased survival rates in patients.
📊
Key Findings & Data:The high prevalence of chronic kidney disease in the general population and the increased incidence of cancer highlight the need for nephrology consultation regarding this issue.
💡
Conclusion & Impact:Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Novel, targeted anticancer therapies have increased survival rates in patients. However, the incidence, severity, and pattern of their toxicities are different from those of traditional chemotherapies. The high prevalence of chronic kidney disease in the general population and the increased incidence of cancer highlight the need for nephrology consultation regarding this issue. Here, we review the incidence, mechanisms, and management of adverse renal effects associated with major molecular, targeted cancer therapies. Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.

🔖

Cite This Article

AKSU, Ö. B., SADİOĞLU, R. E., ŞENGÜL, Ş. (2020). Molecular Targeted Cancer Therapies and the Kidney. Turkish journal of nephrology (Online), Cilt: 29 - Sayı: 3, 232–241. https://ajindex.com/articles/374928

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. DeVita Jr VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012; 366: 2207-14. [Crossref] 2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17. [Crossref] 3. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 2009; 122: 322-8. [Crossref] 4. Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant 2017; 32: 924-36. [Crossref] 5. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46: 439-48. [Crossref] 6. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15: 6250-7. [Crossref] 7. Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: A systematic review and meta-analysis. World J Surg Oncol 2013; 11: 306. [Crossref] 8. Abbas A, Mirza MM, Ganti AK, Tendulkar K. Renal toxicities of targeted therapies. Target Oncol 2015; 10: 487-99. [Crossref] 9. Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): An 8-year observational study at a single center. Medicine (Baltimore) 2014; 93: 333-9. [Crossref] 10. Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22: 988-90. [Crossref] 11. Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review. Kidney Int Rep 2017; 2: 108-23. [Crossref] 12. Wang-Rosenke Y, Khadzhynov D, Loof T, Mika A, Kawachi H, Neumayer HH, et al. Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat. BMC Nephrol 2013; 14: 223. [Crossref] 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-104.